Literature DB >> 18286870

Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study.

Amber Jennex1, David M Gardner.   

Abstract

OBJECTIVE: To evaluate the screening, monitoring, and management of metabolic risk factors and diseases in long-term antipsychotic users in relation to current practice guidelines and current standards of care as represented by a control group from an HIV clinic.
METHODS: We undertook a retrospective chart review of mental health clinic outpatients taking antipsychotic drugs long-term (cases) and HIV outpatients prescribed highly active antiretroviral therapy (control subjects).
RESULTS: We included 99 mental health clinic patients and 98 HIV patients in the analysis. According to information available in the outpatient clinic chart, the 10-year coronary artery disease risk was computable for 28% of the mental health clinic patients (mean risk 11.9%) and for 90% of the HIV patients (mean risk 9.5%) (chi2 = 77.0, P < 0.001). Metabolic risk factors were less frequently documented in mental health clinic charts. All HIV clinic patients were screened for hypertension and diabetes, and 90% were screened for dyslipidemia, whereas this information was missing for 30%, 39%, and 60% of mental health clinic patients, respectively (P < 0.001 for all). Disease monitoring was also more comprehensive in HIV clinic charts (for example, 100% of HIV patients were monitored for lipids, compared with 71% of mental health clinic patients; P = 0.001).
CONCLUSIONS: Improved efforts are needed in the somatic care of patients with bipolar disorder and schizophrenia who are taking antipsychotics, given that they typically have moderate-to-high risk for metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286870     DOI: 10.1177/070674370805300106

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  12 in total

1.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  The overdiagnosis of bipolar disorder.

Authors:  Ioana Iordache; Nancy C Low
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

3.  [Detection of cardiovascular risk factors in patients with psychosis].

Authors:  Lydia Viñas; Maribel Fernández; Luisa San Emeterio; Luis M Martín-López
Journal:  Aten Primaria       Date:  2011-01-06       Impact factor: 1.137

4.  Cardiovascular risk assessment and management in mental health clients: whose role is it anyway?

Authors:  Amanda J Wheeler; Jeff Harrison; Priya Mohini; Jeshika Nardan; Amy Tsai; Eve Tsai
Journal:  Community Ment Health J       Date:  2009-08-18

5.  Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics.

Authors:  Mark E Schneiderhan; Sara M Shuster; Cynthia S Davey
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-30

6.  Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Authors:  Lizheng Shi; Haya Ascher-Svanum; Yi-Ju Chiang; Yingnan Zhao; Vivian Fonseca; Daniel Winstead
Journal:  BMC Psychiatry       Date:  2009-12-18       Impact factor: 3.630

7.  Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.

Authors:  Sameed Ahmed M Khatana; Joshua Kane; Tracey H Taveira; Mark S Bauer; Wen-Chih Wu
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

8.  Predicting implementation from organizational readiness for change: a study protocol.

Authors:  Christian D Helfrich; Dean Blevins; Jeffrey L Smith; P Adam Kelly; Timothy P Hogan; Hildi Hagedorn; Patricia M Dubbert; Anne E Sales
Journal:  Implement Sci       Date:  2011-07-22       Impact factor: 7.327

9.  Psychiatric pharmacist integration into the medical home.

Authors:  Jerry R McKee; Kelly C Lee; Carla D Cobb
Journal:  Prim Care Companion CNS Disord       Date:  2013

10.  Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation.

Authors:  Richard R Owen; Karen L Drummond; Kristen M Viverito; Kathy Marchant; Sandra K Pope; Jeffrey L Smith; Reid D Landes
Journal:  Implement Sci       Date:  2013-10-08       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.